Skip to main content
OpenTrials
Completed

NCT Number: NCT07550829

Effects of CE on the Risk of Arteriosclerosis in SED Postmenopausal Women

This study investigated the effects of three exercise modalities: aerobic exercise, resistance exercise, and combined exercise on the risk of arteriosclerosis in sedentary postmenopausal women.

Completed

Looking for future studies?

Notify Me

Key information

Age range

45 year–69 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

School of Sports Medicine and Rehabilitation, Beijing Sport University

Beijing, China

About this study

This study aims to compare the effects of different kinds of exercise on the risk of arteriosclerosis in sedentary postmenopausal women. Participants were recruited and randomly assigned to aerobic exercise, resistance exercise, combined exercise or control group. The intervention lasted for 12 weeks. Endothelial function indicators, chronic inflammation indicators, arteriosclerosis related indicators, blood pressure indicators were assessed before and after the intervention.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Participants have been postmenopausal for more than 12 months and have not received any exogenous estrogen supplementation after menopause.
  • Participants were screened using the International Physical Activity Questionnaire-Short Form (IPAQ-S), with a physical activity level classified as "low." They must not have engaged in moderate-intensity physical activity for at least 3 days per week, with a duration of no less than 30 minutes per day, for over 3 consecutive months.
  • Participants were screened using the Physical Activity Readiness Questionnaire+ (PAR-Q+) and be deemed safe to undergo further intervention.

Exclusion criteria

  • Participants with acute or chronic musculoskeletal disorders, cardiovascular diseases, or similar conditions.
  • Participants with abnormal blood pressure: resting systolic blood pressure >140 mmHg or diastolic blood pressure >90 mmHg, or those taking antihypertensive medications.
  • Participants with abnormally high arterial stiffness (within pathological range): brachial-ankle pulse wave velocity (baPWV) >1800 cm/s.
  • Participants recently taken medications that may affect blood indicators, such as hormones or anti-inflammatory drugs.
  • Participants with unstable body weight in the past 3 months (fluctuation greater than ±2.5 kg).
  • Participants currently participating in other intervention studies or those with regular exercise habits in daily life.
  • Participants who smoke or consume alcohol regularly.

Treatment and study plan

AE group

Behavioral

Aerobic exercise

RE group

Behavioral

Resistance exercise

CE group

Behavioral

Combined exercise

ON group

Behavioral

No intervention

Primary outcomes

  1. Flow mediated dilation (FMD)

    Time frame: 12 weeks

    The change of flow mediated dilation before and after intervention.

  2. Brachial ankle pulse wave velocity (baPWV)

    Time frame: 12 weeks

    The change of baPWV before and after intervention.

  3. Ankle brachial index (ABI)

    Time frame: 12 weeks

    The change of ABI before and after intervention.

  4. Carotid intima-media thickness (cIMT)

    Time frame: 12 weeks

    The change of cIMT before and after intervention.

  5. Systolic blood pressure (SBP)

    Time frame: 12 weeks

    The change of SBP before and after intervention.

  6. Diastolic blood pressure (DBP)

    Time frame: 12 weeks

    The change of DBP before and after intervention.

  7. Peak systolic velocity (PSV)

    Time frame: 12 weeks

    The change of PSV of carotid artery before and after intervention.

  8. End diastolic velocity (EDV)

    Time frame: 12 weeks

    The change of EDV of carotid artery before and after intervention.

  9. Pulsatility index (PI)

    Time frame: 12 weeks

    The change of PI of carotid artery before and after intervention.

  10. Resistance index (RI)

    Time frame: 12 weeks

    The change of RI of carotid artery before and after intervention.

  11. Wall Shear Stress (WSS)

    Time frame: 12 weeks

    The change of WSS of carotid artery before and after intervention.

Secondary outcomes

  1. Nitric oxide (NO)

    Time frame: 12 weeks

    The change of serum NO before and after intervention.

  2. Prostacyclin (PGI2)

    Time frame: 12 weeks

    The change of serum PGI2 before and after intervention.

  3. Endothelin-1 (ET-1)

    Time frame: 12 weeks

    The change of serum ET-1 before and after intervention.

  4. Angiotensin II (AngII)

    Time frame: 12 weeks

    The change of serum AngII before and after intervention.

  5. C-Reactive protein (CRP)

    Time frame: 12 weeks

    The change of serum CRP before and after intervention.

  6. Interleukin-6 (IL-6)

    Time frame: 12 weeks

    The change of serum IL-6 before and after intervention.

  7. Estrogen

    Time frame: 12 weeks

    The change of serum estrogen before and after intervention.

  8. Soluble intercellular adhesion molecule-1(sICAM-1)

    Time frame: 12 weeks

    The change of serum sICAM-1 before and after intervention.

  9. Soluble vascular cell adhesion molecule-1 (sVCAM-1)

    Time frame: 12 weeks

    The change of serum sVCAM-1 before and after intervention.

  10. Total Cholesterol (TC)

    Time frame: 12 weeks

    The change of serum TC before and after intervention.

  11. High-density lipoprotein cholesterol (HDL-C)

    Time frame: 12 weeks

    The change of serum HDL-C before and after intervention.

  12. Low-density lipoprotein cholesterol (LDL-C)

    Time frame: 12 weeks

    The change of serum LDL-C before and after intervention.

  13. Left ventricular posterior wall thickness at end-diastole (LVPWd)

    Time frame: 12 weeks

    The change of LVPWd before and after intervention.

  14. Left ventricular posterior wall thickness at end-systole (LVPWs)

    Time frame: 12 weeks

    The change of LVPWs before and after intervention.

  15. Stroke volume (SV)

    Time frame: 12 weeks

    The change of SV before and after intervention.

  16. Heart rate (HR)

    Time frame: 12 weeks

    The change of HR before and after intervention.

  17. Left ventricular ejection fraction (LVEF)

    Time frame: 12 weeks

    The change of LVEF before and after intervention.

  18. Cardiac output (CO)

    Time frame: 12 weeks

    The change of CO before and after intervention.

  19. Endothelial Nitric Oxide Synthase (eNOS)

    Time frame: 12 weeks

    The change of serum eNOS before and after intervention.

  20. Maximal oxygen uptake (VO2max)

    Time frame: 12 weeks

    The change of VO2max before and after intervention.

  21. Body mass index (BMI)

    Time frame: 12 weeks

    The change of BMI before and after intervention.

  22. Body fat weight

    Time frame: 12 weeks

    The change of body fat weight before and after intervention.

  23. Body fat%

    Time frame: 12 weeks

    The change of body fat% before and after intervention.

  24. Pittsburgh sleep quality index (PSQI)

    Time frame: 12 weeks

    The change of PSQI before and after intervention.

  25. Food frequency questionnaire (FFQ)

    Time frame: 12 weeks

    The change of FFQ before and after intervention.

  26. Cluster of Differentiation 14 (CD14) mRNA and Protein Expression

    Time frame: 12 weeks

    The change of CD14 mRNA and Protein Expression before and after intervention.

  27. Mitogen-activated protein kinase 14 (MAPK14) mRNA

    Time frame: 12 weeks

    The change of MAPK14 mRNA before and after intervention.

  28. p38 Mitogen-activated protein kinase (p38 MAPK) Protein Expression

    Time frame: 12 weeks

    The change of p38 MAPK Protein Expression before and after intervention.

  29. Tetraspanin 4 (TSPAN4) mRNA and Protein Expression

    Time frame: 12 weeks

    The change of TSPAN4 mRNA and Protein Expression before and after intervention.

  30. Nitric Oxide Synthase 3 (NOS3) mRNA and Protein Expression

    Time frame: 12 weeks

    The change of NOS3 mRNA and Protein Expression before and after intervention.

Sponsors and collaborators

Lead sponsor

Beijing Sport University

Other

Registry information

Official study title

Effects of Combined Exercise on the Risk of Arteriosclerosis in Sedentary Postmenopausal Women

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
Apr 24, 2026
Registry last updated
Apr 24, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.